CN1243827A - 一种特定物理形态的杂环酰胺衍生物的制备方法 - Google Patents
一种特定物理形态的杂环酰胺衍生物的制备方法 Download PDFInfo
- Publication number
- CN1243827A CN1243827A CN98121369A CN98121369A CN1243827A CN 1243827 A CN1243827 A CN 1243827A CN 98121369 A CN98121369 A CN 98121369A CN 98121369 A CN98121369 A CN 98121369A CN 1243827 A CN1243827 A CN 1243827A
- Authority
- CN
- China
- Prior art keywords
- compound
- shape
- physical aspect
- physical
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9027014.1 | 1990-12-12 | ||
GB909027014A GB9027014D0 (en) | 1990-12-12 | 1990-12-12 | Pharmaceutical agents |
GB9115107.6 | 1991-07-12 | ||
GB919115107A GB9115107D0 (en) | 1991-07-12 | 1991-07-12 | Pharmaceutical agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91111566A Division CN1043405C (zh) | 1990-12-12 | 1991-12-11 | 含杂环酰胺衍生物的药物组合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1243827A true CN1243827A (zh) | 2000-02-09 |
CN1105705C CN1105705C (zh) | 2003-04-16 |
Family
ID=26298105
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91111566A Expired - Lifetime CN1043405C (zh) | 1990-12-12 | 1991-12-11 | 含杂环酰胺衍生物的药物组合物的制备方法 |
CN98121369A Expired - Lifetime CN1105705C (zh) | 1990-12-12 | 1998-10-14 | 一种特定物理形态的杂环酰胺衍生物的制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91111566A Expired - Lifetime CN1043405C (zh) | 1990-12-12 | 1991-12-11 | 含杂环酰胺衍生物的药物组合物的制备方法 |
Country Status (30)
Country | Link |
---|---|
US (6) | US5319097A (zh) |
EP (1) | EP0490648B1 (zh) |
JP (1) | JP2585495B2 (zh) |
KR (2) | KR0183027B1 (zh) |
CN (2) | CN1043405C (zh) |
AP (1) | AP285A (zh) |
AT (1) | ATE131048T1 (zh) |
AU (1) | AU656157B2 (zh) |
BE (1) | BE1004229A5 (zh) |
CA (2) | CA2056066C (zh) |
CZ (1) | CZ283181B6 (zh) |
DE (2) | DE4140858A1 (zh) |
DK (1) | DK0490648T3 (zh) |
ES (1) | ES2079589T3 (zh) |
FI (1) | FI101193B (zh) |
FR (1) | FR2670488B1 (zh) |
GB (2) | GB2280606B (zh) |
GR (1) | GR3018318T3 (zh) |
HK (2) | HK81397A (zh) |
HU (2) | HU213211B (zh) |
IE (1) | IE75348B1 (zh) |
IL (1) | IL100091A (zh) |
IT (1) | IT1256282B (zh) |
MX (1) | MX9102473A (zh) |
MY (1) | MY106315A (zh) |
NZ (1) | NZ240939A (zh) |
PH (1) | PH30928A (zh) |
RU (1) | RU2106140C1 (zh) |
SK (2) | SK279813B6 (zh) |
TW (1) | TW276181B (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
GB9119001D0 (en) * | 1991-09-05 | 1991-10-23 | Ici Plc | Pharmaceutical agents |
GR1001368B (el) * | 1992-10-08 | 1993-10-29 | Ici Plc | Φαρμακευτικοί φορείς. |
DE4235133A1 (de) * | 1992-10-19 | 1994-04-21 | Bayer Ag | Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid |
DE9410461U1 (de) * | 1994-07-01 | 1994-09-22 | Merck Patent Gmbh, 64293 Darmstadt | Mittel für die Röntgenfluoreszenzanalyse |
US6279736B1 (en) | 1995-04-19 | 2001-08-28 | Capitol Specialty Plastics, Inc. | Barrier pack having an absorbing agent applied to the interior of the pack |
IN182496B (zh) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
USRE43932E1 (en) | 1997-07-18 | 2013-01-15 | Novartis Ag | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
GB9723985D0 (en) * | 1997-11-14 | 1998-01-14 | Zeneca Ltd | Pharmaceutical compositions |
GB9726735D0 (en) * | 1997-12-18 | 1998-02-18 | Zeneca Ltd | Pharmaceutical compositions |
US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6224907B1 (en) * | 1998-03-06 | 2001-05-01 | Alza Corporation | Anti-asthma therapy |
KR100283682B1 (ko) * | 1998-07-14 | 2001-03-02 | 조정래 | 열풍건조장치 |
US6253463B1 (en) | 1999-04-26 | 2001-07-03 | Niro A/S | Method of spray drying |
IN191496B (zh) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
KR20020032611A (ko) * | 1999-09-20 | 2002-05-03 | 스톤 스티븐 에프. | 약물의 다형성 전환을 경감시키기 위한 공정 |
IL139243A0 (en) * | 2000-10-24 | 2001-11-25 | Internat Specialty Products Is | Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof |
IL140096A0 (en) * | 2000-12-05 | 2002-02-10 | Internat Specialty Products Is | Process for preparation of zafirlukast |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
CZ309209B6 (cs) * | 2001-01-26 | 2022-05-25 | Schering Corporation | Farmaceutický prostředek |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
MXPA04000294A (es) * | 2001-07-10 | 2004-05-04 | Pharmacia & Upjhon Company | Tiacin oxazolidinonas cristalinas. |
GEP20063777B (en) | 2001-08-15 | 2006-03-27 | Upjohn Co | Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof |
EP1429756B1 (en) * | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009501A (es) * | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
US20090317476A1 (en) * | 2003-07-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
US20050113410A1 (en) * | 2003-11-03 | 2005-05-26 | Mark Tawa | Pharmaceutical salts of zafirlukast |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
WO2006096462A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
US20070197467A1 (en) * | 2006-02-06 | 2007-08-23 | Srinivasulu Rangineni | Zafirlukast compositions |
US20090012146A1 (en) * | 2007-07-02 | 2009-01-08 | Giridhar Reddy Buggana | Solubility-enhanced pharmaceutical compositions comprising zafirlukast |
WO2009018280A2 (en) * | 2007-07-30 | 2009-02-05 | Auspex Pharamaceuticals, Inc. | Substituted indoles |
US20090149662A1 (en) * | 2007-12-05 | 2009-06-11 | Raghupathi Reddy Anumula | Processes for preparing zafirlukast |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
EP3096760A1 (en) | 2014-01-22 | 2016-11-30 | Takeda GmbH | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
PT109030B (pt) | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
JP7272655B2 (ja) | 2017-01-30 | 2023-05-12 | ウェスタン ニュー イングランド ユニバーシティ | チオールイソメラーゼ阻害剤およびその使用 |
WO2019130334A1 (en) | 2017-12-28 | 2019-07-04 | Council Of Scientific & Industrial Research | Process for the preparation of zafirlukast and analogs thereof |
CA3219671A1 (en) | 2021-05-19 | 2022-11-24 | Thomas Christian Lines | Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis |
WO2023214391A1 (en) | 2022-05-06 | 2023-11-09 | Quercis Pharma AG | Method for treating cancers and neurological diseases using quercetin-containing compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
GB9027018D0 (en) * | 1990-12-12 | 1991-01-30 | Ici Plc | Heterocyclic compounds |
-
1991
- 1991-11-19 IL IL10009191A patent/IL100091A/en not_active IP Right Cessation
- 1991-11-22 CA CA002056066A patent/CA2056066C/en not_active Expired - Lifetime
- 1991-11-22 CA CA002319308A patent/CA2319308C/en not_active Expired - Lifetime
- 1991-12-09 HU HU913865A patent/HU213211B/hu unknown
- 1991-12-10 MX MX9102473A patent/MX9102473A/es unknown
- 1991-12-10 TW TW080109698A patent/TW276181B/zh not_active IP Right Cessation
- 1991-12-11 ES ES91311504T patent/ES2079589T3/es not_active Expired - Lifetime
- 1991-12-11 GB GB9418154A patent/GB2280606B/en not_active Expired - Lifetime
- 1991-12-11 FR FR9115366A patent/FR2670488B1/fr not_active Expired - Fee Related
- 1991-12-11 US US07/805,421 patent/US5319097A/en not_active Expired - Lifetime
- 1991-12-11 IE IE431091A patent/IE75348B1/en not_active IP Right Cessation
- 1991-12-11 AU AU88994/91A patent/AU656157B2/en not_active Expired
- 1991-12-11 EP EP91311504A patent/EP0490648B1/en not_active Expired - Lifetime
- 1991-12-11 KR KR1019910022917A patent/KR0183027B1/ko not_active IP Right Cessation
- 1991-12-11 DK DK91311504.4T patent/DK0490648T3/da active
- 1991-12-11 SK SK3756-91A patent/SK279813B6/sk not_active IP Right Cessation
- 1991-12-11 FI FI915826A patent/FI101193B/fi not_active IP Right Cessation
- 1991-12-11 IT ITMI913324A patent/IT1256282B/it active IP Right Grant
- 1991-12-11 DE DE4140858A patent/DE4140858A1/de not_active Withdrawn
- 1991-12-11 CZ CS913756A patent/CZ283181B6/cs not_active IP Right Cessation
- 1991-12-11 NZ NZ240939A patent/NZ240939A/en not_active IP Right Cessation
- 1991-12-11 RU SU5010340/14A patent/RU2106140C1/ru active
- 1991-12-11 MY MYPI91002302A patent/MY106315A/en unknown
- 1991-12-11 GB GB9126354A patent/GB2251791B/en not_active Expired - Lifetime
- 1991-12-11 AT AT91311504T patent/ATE131048T1/de not_active IP Right Cessation
- 1991-12-11 DE DE69115229T patent/DE69115229T2/de not_active Expired - Lifetime
- 1991-12-11 BE BE9101127A patent/BE1004229A5/fr not_active IP Right Cessation
- 1991-12-11 JP JP3327783A patent/JP2585495B2/ja not_active Expired - Fee Related
- 1991-12-11 PH PH43619A patent/PH30928A/en unknown
- 1991-12-11 CN CN91111566A patent/CN1043405C/zh not_active Expired - Lifetime
- 1991-12-11 AP APAP/P/1991/000340A patent/AP285A/en active
-
1993
- 1993-09-03 US US08/116,781 patent/US5482963A/en not_active Expired - Lifetime
-
1995
- 1995-03-13 US US08/403,132 patent/US5504216A/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,191 patent/US5612367A/en not_active Expired - Lifetime
- 1995-06-09 HU HU95P/P00181P patent/HU211126A9/hu unknown
- 1995-12-07 GR GR950403190T patent/GR3018318T3/el unknown
-
1996
- 1996-08-30 KR KR1019960036692A patent/KR100207802B1/ko not_active IP Right Cessation
-
1997
- 1997-06-19 HK HK81397A patent/HK81397A/xx not_active IP Right Cessation
- 1997-06-19 HK HK81597A patent/HK81597A/xx not_active IP Right Cessation
-
1998
- 1998-05-20 SK SK664-98A patent/SK279814B6/sk not_active IP Right Cessation
- 1998-07-13 US US09/114,225 patent/US5993859A/en not_active Expired - Lifetime
- 1998-10-14 CN CN98121369A patent/CN1105705C/zh not_active Expired - Lifetime
-
1999
- 1999-11-23 US US09/447,414 patent/US6143775A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1105705C (zh) | 一种特定物理形态的杂环酰胺衍生物的制备方法 | |
CN1174991C (zh) | 克拉霉素的o型结晶 | |
EP2217214A2 (en) | Pharmaceutical formulation comprising ezetimibe | |
CN103068232A (zh) | 多晶型物形式st-246和制备方法 | |
CN1821249A (zh) | 无结晶型态的印地普隆及其制备方法 | |
CN103570621A (zh) | 一种(-)-石杉碱甲的制备 | |
CN101039906A (zh) | 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法,所述有机溶剂为醇和酮和 /或酯的混合物 | |
CN1633439A (zh) | 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 | |
CN1931159B (zh) | 艾拉莫德微粉化及口服速释制剂 | |
CN1807417A (zh) | 新型无水无结晶型态的罗伐他汀钙盐 | |
CN100341495C (zh) | 格列本脲固体分散体、口服组合物及其制备方法 | |
AU3095600A (en) | New pharmaceutical formulation | |
US20080014263A1 (en) | Amorphous eprosartan mesylate and process for the preparation thereof | |
WO2008110339A2 (en) | Polymorphs of rivastigmine hydrogentartrate | |
CN1903869A (zh) | 替比夫定的衍生物盐及其制备方法和药物应用 | |
CN1878538A (zh) | 用于治疗肥胖的mtp抑制剂的固体无定形分散体 | |
FI106021B (fi) | Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi | |
CN1674902A (zh) | 新晶型的加替沙星 | |
CN100999510A (zh) | 无结晶型态草酸依地普仑及其共沉淀物的制备 | |
CN1660846A (zh) | 无结晶型态的恩替卡韦 | |
PT100508B (pt) | Composicoes farmaceuticas e processo para a sua preparacao |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ASTRAZENECA (UK) LIMITED Free format text: FORMER OWNER: SIGENTIS CO., LTD. Effective date: 20061229 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SIGENTIS CO., LTD. Free format text: FORMER NAME OR ADDRESS: ZENECA LTD |
|
CP03 | Change of name, title or address |
Address after: surrey Patentee after: SYNGENTA LTD. Address before: England Patentee before: ZENECA Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20061229 Address after: London, England Patentee after: ASTRAZENECA UK LTD. Address before: surrey Patentee before: SYNGENTA LTD. |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20111211 Granted publication date: 20030416 |